Biosante Pharmaceuticals, Inc.

biosante´s corporate strategy is to develop high value medically-needed pharmaceutical products and to implement strategic alternatives with respect to its products and its company, including licenses, business collaborations and other business combinations or transactions with other pharmaceutical and biotechnology companies. biosante´s products include libigel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (fsd), specifically hypoactive sexual desire disorder (hsdd), which is in phase iii clinical development. biosante also is developing a portfolio of cancer vaccines, with 17 phase i and phase ii clinical trials currently on-going. four of these vaccines have been granted orphan drug designation by the u.s. food and drug administration (fda). biosante´s other products include an fda-approved testosterone gel for male hypogonadism, which is licensed to teva pharmaceuticals usa, inc., and the pill-plus™, an oral contraceptive in phase ii clinical develo